Nuvation Bio, Inc. (NUVB)
5.14
-0.42
(-7.55%)
USD |
NYSE |
Oct 02, 16:00
5.17
+0.03
(+0.58%)
Pre-Market: 20:00
Nuvation Bio Enterprise Value : 1.553B for Oct. 2, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 02, 2026 | 1.553B |
| October 01, 2026 | 1.700B |
| September 30, 2026 | 1.714B |
| September 29, 2026 | 1.721B |
| September 28, 2026 | 1.714B |
| September 25, 2026 | 1.763B |
| September 24, 2026 | 1.760B |
| September 23, 2026 | 1.753B |
| September 22, 2026 | 1.889B |
| September 21, 2026 | 1.879B |
| September 18, 2026 | 1.802B |
| September 17, 2026 | 1.879B |
| September 16, 2026 | 1.777B |
| September 15, 2026 | 1.784B |
| September 14, 2026 | 1.833B |
| September 11, 2026 | 1.879B |
| September 10, 2026 | 1.952B |
| September 09, 2026 | 2.036B |
| September 08, 2026 | 2.068B |
| September 04, 2026 | 2.138B |
| September 03, 2026 | 2.124B |
| September 02, 2026 | 2.180B |
| September 01, 2026 | 2.078B |
| August 31, 2026 | 2.085B |
| August 28, 2026 | 2.085B |
| Date | Value |
|---|---|
| August 27, 2026 | 2.201B |
| August 26, 2026 | 2.190B |
| August 25, 2026 | 2.239B |
| August 24, 2026 | 2.120B |
| August 21, 2026 | 2.180B |
| August 20, 2026 | 2.145B |
| August 19, 2026 | 2.295B |
| August 18, 2026 | 2.190B |
| August 17, 2026 | 2.022B |
| August 14, 2026 | 1.931B |
| August 13, 2026 | 1.889B |
| August 12, 2026 | 2.001B |
| August 11, 2026 | 1.984B |
| August 10, 2026 | 2.064B |
| August 07, 2026 | 2.064B |
| August 06, 2026 | 1.893B |
| August 05, 2026 | 1.984B |
| August 04, 2026 | 2.008B |
| August 03, 2026 | 1.910B |
| July 31, 2026 | 1.970B |
| July 30, 2026 | 2.099B |
| July 29, 2026 | 2.061B |
| July 28, 2026 | 2.096B |
| July 27, 2026 | 2.085B |
| July 24, 2026 | 2.001B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Bristol Myers Squibb Co. | 158.92B |
| Johnson & Johnson | 644.86B |
| Pfizer Inc. | 210.23B |
| Eli Lilly & Co. | 1.122T |
| Merck & Co., Inc. | 403.00B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -62.84M |
| Revenue (Quarterly) | 31.69M |
| Total Expenses (Quarterly) | 94.53M |
| EPS Diluted (Quarterly) | -0.1802 |
| Gross Profit Margin (Quarterly) | 68.42% |
| Profit Margin (Quarterly) | -198.3% |
| Earnings Yield | -8.47% |
| Normalized Earnings Yield | -8.179 |